Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $139.4 million.

  • Ligand Pharmaceuticals' Cash & Equivalents rose 11907.92% to $139.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.4 million, marking a year-over-year increase of 11907.92%. This contributed to the annual value of $72.3 million for FY2024, which is 21500.83% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Cash & Equivalents stood at $139.4 million for Q3 2025, which was up 11907.92% from $67.7 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Cash & Equivalents registered a high of $139.4 million during Q3 2025, and its lowest value of $4.1 million during Q3 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $28.4 million (2023), whereas its average is $41.3 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Cash & Equivalents plummeted by 9487.21% in 2021 and then skyrocketed by 49179.62% in 2023.
  • Ligand Pharmaceuticals' Cash & Equivalents (Quarter) stood at $19.5 million in 2021, then surged by 130.54% to $45.0 million in 2022, then tumbled by 49.0% to $23.0 million in 2023, then skyrocketed by 215.01% to $72.3 million in 2024, then skyrocketed by 92.76% to $139.4 million in 2025.
  • Its Cash & Equivalents was $139.4 million in Q3 2025, compared to $67.7 million in Q2 2025 and $48.0 million in Q1 2025.